Pushing the boundaries of science to deliver breakthrough therapies
Altriva's R&D engine combines deep biological insights with cutting-edge technology platforms to discover and develop transformative medicines.
With an annual R&D budget exceeding $200 million, Altriva operates three state-of-the-art research centers in the United States. Our capabilities span the full drug development spectrum:
Biomarker-driven drug development targeting specific genetic mutations. Our precision oncology platform leverages comprehensive genomic profiling to identify patient populations most likely to respond.
Advanced formulation technologies including nanoparticle drug delivery, sustained-release matrices, and novel bioavailability enhancement for improved patient outcomes.
Machine learning algorithms for drug-target interaction prediction, molecular optimization, and clinical trial design. Reducing development timelines by up to 30%.
End-to-end biologics capabilities including monoclonal antibody discovery, protein engineering, and cell line development for complex therapeutic modalities.
Global, randomized, open-label trial evaluating AP-201 versus standard of care in EGFR-mutant non-small cell lung cancer. 450 patients enrolled across 60 centers. Primary completion: Q1 2027.
Double-blind, placebo-controlled trial evaluating oral AP-701 for acute treatment of migraine with or without aura. 1,200 patients randomized. Topline results expected Q4 2026.
Phase II study of AP-412 as maintenance therapy in BRCA-mutated advanced ovarian cancer. 15 sites across US and Europe actively recruiting.
Randomized, double-blind, dose-ranging study evaluating safety and efficacy of AP-801 in early-stage Parkinson's disease. Enrollment ongoing.
Published in Journal of Clinical Oncology, March 2026. Phase I/II data demonstrating durable responses in T790M-positive NSCLC.
Nature Drug Discovery Review, January 2026. Altriva's AI platform identified 3 novel indications for existing compounds.
New England Journal of Medicine, December 2025. Pivotal trial results for AP-601 anticoagulant showing superior safety profile.